Immunovant, Inc.IMVTNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Latest
-62.15%
↑ 100% vs avg
Percentile
P29
Within normal range
Streak
1 yr
Consecutive declineDecelerating
Average
-1657728.58%
Historical baseline
PeriodValue
2025-62.15%
2024-29.74%
2023-33.48%
2022-44.32%
2021-81.17%
2020-13261677.78%
2019100.00%
20180.00%